GAIT

(redirected from Glucosamine/chondroitin Arthritis Intervention Trial)
AcronymDefinition
GAITGlucosamine/chondroitin Arthritis Intervention Trial (NIH)
GAITGraphic Arts and Imaging Technology (various schools)
GAITGSM/ANSI-136 Interoperability Team
GAITGenerally Accepted IT Principles
GAITGSM ANSI-41 Interoperability Team (cellular technology)
GAITGlobal Alpine Institute of Technology
GAITGround/Airborne Integrated Terminal (GPS)
References in periodicals archive ?
The glucosamine/chondroitin Arthritis Intervention Trial ("GAIT Trial") found no evidence for effective pain reduction in knee osteoarthritis; however, a subgroup analysis noted a statistical trend toward pain relief in patients with moderate to severe knee pain.
The combination of glucosamine and chondroitin sulfate has been shown to aid moderate-to-severe knee OA, but showed no benefit to patients with mild knee OA pain, according to the Glucosamine/Chondroitin Arthritis Intervention Trial (Arthritis & Rheumatology, November 2014).
A recent, two-year study sponsored by the National Institutes of Health called the Glucosamine/Chondroitin Arthritis Intervention Trial found that 79 percent of the 354 participants with moderate to severe knee pain due to OA experienced twenty percent less pain and improved function with a combination of glucosamine (1500 mg a day) and chondroitin sulfate (1200 mg a day.) However, more research is needed to confirm these findings.
The Glucosamine/Chondroitin Arthritis Intervention Trial found that patients with moderate to severe arthritis knee pain received pain relief from glucosamine and chondroitin.
The dietary supplements glucosamine and chondroitin sulfate, together or alone, appeared to fare no better than placebo in slowing loss of cartilage in osteoarthritis of the knee, researchers from the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) team report in the October issue of "Arthritis & Rheumatism." "While these results are of interest, we cannot draw definitive conclusions about the utility of glucosamine or chondroitin in reducing joint space width loss, in part because the placebo group fared better than anticipated based on prior research results," said Josephine P.
(17) The 2006 Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), (18) sponsored by the National Institutes of Health, showed conflicting and somewhat confusing results.
(38) The NIH-sponsored Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), which enrolled 1583 patients with painful knee OA, (39) failed to reveal an effect of glucosamine or chondroitin alone or in combination when compared to placebo.
Patients were 45-80 years old, with a mean body mass index of 29 kg/[m.sup.2], and were less overweight than patients in some similar trials such as the National Institutes of Health's Glucosamine/Chondroitin Arthritis Intervention Trial.
The National Institutes of Health's recently completed Glucosamine/chondroitin Arthritis Intervention Trial, for instance, found that taking the two supplements together is more effective on relieving osteoarthritis knee pain than the prescription medication Celebrex.
The Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) randomized 1,583 patients with symptomatic osteoarthritis to receive 1,500 mg/day of glucosamine HCl, 1,200 mg/day of chondroitin sulfate, a combination of the two supplements in those same doses, 200 mg/day of celecoxib, or placebo for 3 months.